Link between anti-CD36 antibodies and thrombosis in the antiphospholipid syndrome.

Abstract

OBJECTIVE:

Some studies have previously suggested the involvement of antibodies directed against CD36 (anti-CD36) in the pathogenesis of thrombosis. The aim of this study was to evaluate the prevalence of anti-CD36 in patients with antiphospholipid antibodies (aPL) and its relationship with thrombosis.

METHODS:

Anti-CD36 were tested using an indirect MAIPA assay in 62 patients with autoimmune aPL but without SLE; there were 38 with and 24 without thrombosis. Nineteen patients with thrombosis served as an aPL(-) control group and 58 healthy subjects as the normal control group.

RESULTS:

15 of 62 aPL patients (24.2%) but only 1 of 58 (1.7%) normal controls had anti-CD36 (p < 0.0005). As compared to normal controls, the prevalence of anti-CD36 was significantly higher in aPL patients with (26.3%, p < 0.0005) or without thrombosis (20.8%, p < 0.01). Anti-CD36 were significantly more frequent in aPL patients with thrombosis than in thrombosis aPL(-) subjects (26.3% vs 0%, p = 0.02). The presence of anti-CD36 seems to be more frequent in aPL patients with recurrent thrombosis than in those with a single episode (36.8% vs 15.8%).

CONCLUSION:

The presence of anti-CD36 is highly prevalent in patients with autoimmune aPL with a trend to being more frequent in patients with recurrent episodes of thrombosis.

• Authors: Y Pelegri, G Cerrato, M E Martinuzzo, L O Carreras, R R Forastiero
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) 2003 Mar-Apr Vol. 21 Issue 2 Pg. 221-4 ISSN: 0392-856X [Print] Italy
• PMID: 12747279 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Autoantibodies
• CD36 Antigens

Topics

• Adult
• Antiphospholipid Syndrome (complications, immunology)
• Autoantibodies (immunology)
• CD36 Antigens (immunology)
• Female
• Humans
• Male
• Prevalence
• Recurrence
• Thrombosis (complications, immunology)